KU ASH 2018 Review: Current Updates in Hematologic Diseases

 

Videos
22:39

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - MDS - Top Trials and Key Takeaways

FEATURING Barry Skikne
  • 147 views
  • March 8, 2019
25:14

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - MPN - Review and Synthesis of Recent Trials

FEATURING Abdulraheem Yacoub
  • 105 views
  • March 8, 2019
26:11

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH 2018 Myeloid Neoplasms - How Recent Trials on Stem Cell Transplant Therapy Apply to Your Practice

FEATURING Anurag K. Singh
  • 238 views
  • March 8, 2019
  • 1
28:21

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Benign Hematolgy - Analysis of Top Trials

FEATURING Penelope Harris
  • 547 views
  • March 8, 2019
  • 1
30:39

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - CLL and Indolent Lymphoma - Review of Clinical Trials and Treatment Options

FEATURING Marc Hoffmann
  • 569 views
  • March 8, 2019
  • 3
21:22

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018- Aggressive Lymphomas: Recent Approvals and Promising Studies

FEATURING Anusha Vallurupalli
  • 150 views
  • March 8, 2019
  • 2
25:51

KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

FEATURING Al-Ola Abdallah
  • 1,280 views
  • March 8, 2019
  • 8
06:55

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Lymphoma- Historical Perspective of CAR-T Cell Therapy

FEATURING Frederick L. Locke
  • 210 views
  • March 19, 2019
  • 1
24:51

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018- Lymphoma - Efficacy and Safety from ZUMA 1, JULIET and Other Top Trials

FEATURING Frederick L. Locke
  • 380 views
  • March 19, 2019
  • 1
14:52

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Lymphoma - Axi-cel as Standard of Care and Related Trials

FEATURING Frederick L. Locke
  • 200 views
  • March 19, 2019
  • 1
03:50

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - Myeloma - BCMA CAR T Therapy for Refractory Patients

FEATURING Frederick L. Locke
  • 242 views
  • March 19, 2019
23:37

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH 2018 AML: Deciding Between Standard vs Investigational Therapies & Problems in Evaluating New Therapies, MRD and HCT

FEATURING Elihu H. Estey
  • 571 views
  • March 19, 2019
05:54

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - MRD in AML - What is the Benefit / Risk Ratio Related to HCT?

FEATURING Elihu H. Estey
  • 197 views
  • March 19, 2019
06:26

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018 - AML - Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies

FEATURING Elihu H. Estey
  • 42 views
  • March 19, 2019
14:49

KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH 2018 AML Challenges in Evaluating New Therapies: Understanding the Recent FDA Approvals

FEATURING Elihu H. Estey
  • 181 views
  • March 19, 2019
Lymphoma and Myeloma - Cellular Therapy, Efficacy and Safety from Top Trials, Axi-cel, BCMA CAR T Therapy

Lymphoma and Myeloma - Cellular Therapy, Efficacy and Safety from Top Trials, Axi-cel, BCMA CAR T Therapy

Playlist Items:
ASH December 2018 - Lymphoma- Historical Perspective of CAR-T Cell Therapy, The University of Kansas Cancer Center
ASH December 2018- Lymphoma - Efficacy and Safety from ZUMA 1, JULIET and Other Top Trials, The University of Kansas Cancer Center
ASH December 2018 - Lymphoma - Axi-cel as Standard of Care and Related Trials, The University of Kansas Cancer Center
ASH December 2018 - Myeloma - BCMA CAR T Therapy for Refractory Patients, The University of Kansas Cancer Center
  • 20 views
  • March 19, 2019
AML - Keynote - Latest updates on Standard Therapies and Investigational Therapies, MRD in AML, HTC and Non-HCT

AML - Keynote - Latest updates on Standard Therapies and Investigational Therapies, MRD in AML, HTC and Non-HCT

Playlist Items:
ASH 2018 AML: Deciding Between Standard vs Investigational Therapies & Problems in Evaluating New Therapies, MRD and HCT, The University of Kansas Cancer Center
ASH December 2018 - MRD in AML - What is the Benefit / Risk Ratio Related to HCT?, The University of Kansas Cancer Center
ASH December 2018 - AML - Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies, The University of Kansas Cancer Center
ASH 2018 AML Challenges in Evaluating New Therapies: Understanding the Recent FDA Approvals, The University of Kansas Cancer Center
  • 459 views
  • March 19, 2019